COMMUNIQUÉS West-GlobeNewswire
-
SPRINT® PNS Publication Highlights Sustained Benefits in Low Back Pain Patients
07/07/2026 -
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
07/07/2026 -
SkinStylus® Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
07/07/2026 -
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
07/07/2026 -
World First: KFSH Jeddah's Single-Session Stem Cell Protocol Sets a New Global Standard Balancing Donor Safety and Treatment Efficiency
07/07/2026 -
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
07/07/2026 -
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
07/07/2026 -
InStride Health’s New Peer-Reviewed Research Demonstrates Reductions in Caregiver Strain following Specialty Virtual Care for Families of Youth with Anxiety and OCD
07/07/2026 -
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
07/07/2026 -
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
07/07/2026 -
Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up
07/07/2026 -
New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
07/07/2026 -
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
07/07/2026 -
MAPS Publishes Ibogaine Investigator's Brochure as a Free, Open-Access Resource
07/07/2026 -
Carbonium Core CEO Details Strategy to Supply Critical Material Powering the AI-Driven Nuclear Renaissance
07/07/2026 -
Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
07/07/2026 -
Privia Health to Report Second Quarter 2026 Results on Thursday, August 6
07/07/2026 -
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
07/07/2026 -
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
07/07/2026
Pages